Skip to main content

Table 1 Results of safety and efficacy test

From: A gD&gC-substituted pseudorabies virus vaccine strain provides complete clinical protection and is helpful to prevent virus shedding against challenge by a Chinese pseudorabies variant

Groups    A B C D
Virus tested    B-gD&gCS Bartha K61 / /
Dosage    1 × 106 TCID50 PBS /
Inoculation route    Intramuscularly  
ELISA antibodies against PRV gB or gE B.V. gB+ 0a/5b 0/5 0/5 0/5
gE+ 0/5 0/5 0/5 0/5
7d P.V. gB+ 5/5 5/5 0/5 0/5
gE+ 0/5 0/5 0/5 0/5
14 d P.C. gB+ 5/5 5/5 2/5 0/5
gE+ 5/5 5/5 2/5 0/5
Clinical signs P.V.   0/5 0/5 0/5 0/5
Fever frequency (≥40.5 °C) P.V.   0/5 0/5 0/5 0/5
Virus shedding P.V.   0/5 0/5 / /
Fever frequency (≥40.5 °C) P.C.   0/5 0/5 5/5 0/5
Clinical signs P.C. Morbidity 0/5 0/5 5/5 0/5
Duration (days) / / 4~12 /
Mortality 0/5 0/5 3/5 0/5
Virus shedding P.C. Frequency 3/5 5/5 5/5 0/5
Titer (TCID50/g) 102.49~106.19 101.30~109.82 101.30~108.83 /
Duration (days) 1~8 4~10 3~10 /
Lung lesions P.C.   0/5 0/5 5/5 0/5
  1. B.V. before vaccination, P.V. post vaccination, P.C. post challenge, gB+ antibodies against PRV gB positive, gE+ antibodies against PRV gE positive, “/”, not applicable; athe number of piglets positive; bthe number of piglets in the group